Publicaciones en las que colabora con Javier Zulueta Frances (38)

2024

  1. Lung Cancer Screening in People With COPD: The Pamplona-IELCAP Experience

    Archivos de Bronconeumologia, Vol. 60, Núm. 2, pp. 95-100

  2. Prospective Cohort Study to Compare Long-Term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a–b; ≤20 mm) NSCLC Treated by Stereotactic Body Radiation Therapy and Surgery

    Journal of Thoracic Oncology, Vol. 19, Núm. 3, pp. 476-490

  3. Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma

    eBioMedicine, Vol. 102

2023

  1. Circulating proteome for pulmonary nodule malignancy

    Journal of the National Cancer Institute, Vol. 115, Núm. 9, pp. 1060-1070

  2. Lung cancer screening using low-dose CT and FDG-PET in liver transplant recipients

    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, Vol. 29, Núm. 10, pp. 1100-1108

2021

  1. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer

    Translational Research, Vol. 233, pp. 77-91

  2. Endobronchial autologous bone marrow-mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial

    ERJ Open Research, Vol. 7, Núm. 2, pp. 00773-2020

  3. Molecular biomarkers in early stage lung cancer

    Translational Lung Cancer Research, Vol. 10, Núm. 2, pp. 1165-1185

  4. Notch3 deficiency attenuates pulmonary fibrosis and impedes lung-function decline

    American Journal of Respiratory Cell and Molecular Biology, Vol. 64, Núm. 4, pp. 465-476

2020

  1. Avances en el manejo del cáncer de pulmón

    Anales del sistema sanitario de Navarra, Vol. 43, Núm. 2, pp. 131-139

2019

  1. Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges

    Journal of Thoracic Oncology, Vol. 14, Núm. 3, pp. 343-357

  2. CT screening for lung cancer: comparison of three baseline screening protocols

    European Radiology, Vol. 29, Núm. 10, pp. 5217-5226

2017

  1. Telomere length, COPD and emphysema as risk factors for lung cancer

    European Respiratory Journal

2016

  1. A novel epigenetic signature for early diagnosis in lung cancer

    Clinical Cancer Research, Vol. 22, Núm. 13, pp. 3361-3371

2015

  1. Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer

    PLoS ONE, Vol. 10, Núm. 3

  2. Improving selection criteria for lung cancer screening: The potential role of emphysema

    American Journal of Respiratory and Critical Care Medicine, Vol. 191, Núm. 8, pp. 924-931

2013

  1. Investigation of complement activation product C4d as a diagnostic and prognostic biomarker for lung cancer

    Journal of the National Cancer Institute, Vol. 105, Núm. 18, pp. 1385-1393

  2. Smokers with CT Detected Emphysema and No Airway Obstruction Have Decreased Plasma Levels of EGF, IL-15, IL-8 and IL-1ra

    PLoS ONE, Vol. 8, Núm. 4

2012

  1. Re: Inconsistencies in findings from the early lung cancer action project studies of lung cancer screening

    Journal of the National Cancer Institute

2011

  1. Assessment of epidermal growth factor receptor and krasmutation status in cytological stained smears of non-small celllung cancer patients: Correlation with clinical outcomes

    Oncologist, Vol. 16, Núm. 6, pp. 877-885